Travere Therapeutics licenses Everest Medicines’ civorebrutinib outside China in USD 112.5 million deal

Travere Therapeutics, Inc.

Travere Therapeutics, Inc.

TVTX

0.00
  • Travere Therapeutics entered an exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib outside China and parts of East and Southeast Asia.
  • Everest receives an upfront payment of USD 112.5 million.
  • Deal includes up to about USD 1.03 billion in development, regulatory, commercial milestones across up to five indications.
  • Everest also qualifies for tiered royalties from high single-digit to double-digit percentages based on annual net sales thresholds.
  • Travere plans to develop civorebrutinib for immune-mediated kidney diseases, including primary membranous nephropathy, immune-mediated FSGS, minimal change disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606020701BIZWIRE_USPR_____20260602_BW830373) on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.